首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
【24h】

Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma

机译:全转录组测序揭示套细胞淋巴瘤中复发的NOTCH1突变

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma, is characterized by the hallmark translocation t(11;14)(q13;q32) and the resulting overexpression of cyclin D1 (CCND1). Our current knowledge of this disease encompasses frequent secondary cytogenetic aberrations and the recurrent mutation of a handful of genes, such as TP53, ATM, and CCND1. However, these findings insufficiently explain the biologic underpinnings of MCL. Here, we performed whole transcriptome sequencing on a discovery cohort of 18 primary tissue MCL samples and 2 cell lines.We found recurrent mutations in NOTCH1, a finding that we confirmed in an extension cohort of 108 clinical samples and 8 cell lines. In total, 12% of clinical samples and 20% of cell lines harbored somatic NOTCH1 coding sequence mutations that clustered in the PEST domain and predominantly consisted of truncating mutations or small frame-shifting indels. NOTCH1 mutations were associated with poor overall survival (P ? .003). Furthermore, we showed that inhibition of the NOTCH pathway reduced proliferation and induced apoptosis in 2 MCL cell lines. In summary, we have identified recurrent NOTCH1 mutations that provide the preclinical rationale for therapeutic inhibition of the NOTCH pathway in a subset of patients with MCL.
机译:幔细胞淋巴瘤(MCL)是一种非霍奇金淋巴瘤的侵略性亚型,其特征是标志性易位t(11; 14)(q13; q32)和细胞周期蛋白D1(CCND1)的过度表达。我们目前对这种疾病的了解包括频繁的继发性细胞遗传畸变和少数基因(如TP53,ATM和CCND1)的复发突变。但是,这些发现不足以解释MCL的生物学基础。在这里,我们对18个主要组织MCL样品和2个细胞系的发现队列进行了完整的转录组测序,我们在NOTCH1中发现了重复突变,这一发现在108个临床样品和8个细胞系的扩展队列中得到了证实。总的来说,12%的临床样品和20%的细胞系具有体细胞NOTCH1编码序列突变,这些突变聚集在PEST域中,主要由截短突变或小的移码插入/缺失组成。 NOTCH1突变与总体生存不良有关(P≤0.003)。此外,我们表明抑制NOTCH途径减少了2个MCL细胞系的增殖并诱导了其凋亡。总而言之,我们已经确定了复发性的NOTCH1突变,这些突变为MCL患者亚组中的NOTCH途径的治疗性抑制提供了临床前理由。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号